Tracon Pharmaceuticals Says Prostate Cancer Drug Well Tolerated
July 02 2019 - 9:00AM
Dow Jones News
By Chris Wack
Tracon Pharmaceuticals (TCON) on Tuesday said its TRC253 program
for the treatment of metastatic castrate resistant prostate cancer,
which was licensed from Janssen Pharmaceutica N.V. in 2016, was
well tolerated.
The biopharmaceutical company said 21 patients with metastatic
castrate resistant prostate cancer who had progressed on prior
Xtandi enzalutamide or Erleada apalutamide treatment were enrolled
into one of six cohorts of escalating doses of TRC253.
The company said data showed target PK exposures were achieved
consistently with the 280 mg daily oral dose, which was selected as
the recommended Phase 2 dose. TRC253 was well-tolerated and no
drug-related serious adverse events were reported.
Enrollment is ongoing in a new cohort with a defined point
mutation, as well as the two existing cohorts, the first including
patients with a F877L AR mutation and the second consisting of
patients with another basis for resistance to Xtandi or
Erleada.
Following completion of the initial Phase 1/2 clinical trial,
Janssen will have an exclusive option to reacquire full rights to
TRC253 for an upfront payment of $45 million to Tracon, and
obligations to pay regulatory and commercialization milestones
totaling up to $137.5 million upon achievement of specified events
and a low single-digit royalty.
If Janssen doesn't exercise its exclusive option to reacquire
the program, Tracon would then retain worldwide development and
commercialization rights to the program and would be obligated to
pay Janssen a total of up to $45 million in development and
regulatory milestones upon achievement of specified events, in
addition to a low single-digit royalty.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 02, 2019 08:45 ET (12:45 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024